Contact
searchSearch
HMP Global
Login

Acute Lymphoblastic Leukemia Specialty Channel

Acute Lymphoblastic Leukemia
Specialty Channel
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Blinatumomab Added to Consolidation Chemotherapy Improves Overall Survival Among Patients in MRD-Negative Remission From B-Cell Precursor ALL
08/14/2024
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study,...
08/14/2024
Oncology
News
FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL
06/21/2024
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to...
06/21/2024
Oncology
News
Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL
04/09/2024

Jordan Kadish

Jordan Kadish
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial,...
04/09/2024
Oncology
Quiz
Efficacy of Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Following ASCT
04/02/2024
04/02/2024
Oncology
News
Allogeneic Stem Cell Transplantation in First Complete Remission for Patients With Philadelphia Chromosome-Positive ALL
04/01/2024

Jordan Kadish

Jordan Kadish
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia...
04/01/2024
Oncology
FDA Approval
FDA Approves Ponatinib With Chemotherapy for Patients With Newly-Diagnosed Ph-Positive Acute Lymphoblastic Leukemia
03/21/2024

Jordan Kadish

Jordan Kadish
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA...
03/21/2024
Oncology
News
Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Post-Transplantation
03/15/2024

Jordan Kadish

Jordan Kadish
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis...
03/15/2024
Oncology
News
FDA Grants Approval to Inotuzumab Ozogamicin for Pediatric Patients With R/R CD22-Positive B-Cell Precursor ALL
03/07/2024

Jordan Kadish

Jordan Kadish
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA...
03/07/2024
Oncology
News
Chemo-Free Induction/Consolidation With Dasatinib and Blinatumomab Shows Long-Term Responses for Adult Patients With Philadelphia-Positive ALL
02/21/2024
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free...
02/21/2024
Oncology
News
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin, and Blinatumomab Shows Safety, Efficacy Among Patients With Philadelphia Chromosome-Negative B-Cell ALL
02/13/2024
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD,...
02/13/2024
Oncology

News

FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Blinatumomab Added to Consolidation Chemotherapy Improves Overall Survival Among Patients in MRD-Negative Remission From B-Cell Precursor ALL
08/14/2024
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study,...
08/14/2024
Oncology
News
FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL
06/21/2024
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to...
06/21/2024
Oncology
News
Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL
04/09/2024

Jordan Kadish

Jordan Kadish
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial,...
04/09/2024
Oncology
News
Allogeneic Stem Cell Transplantation in First Complete Remission for Patients With Philadelphia Chromosome-Positive ALL
04/01/2024

Jordan Kadish

Jordan Kadish
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia...
04/01/2024
Oncology
FDA Approval
FDA Approves Ponatinib With Chemotherapy for Patients With Newly-Diagnosed Ph-Positive Acute Lymphoblastic Leukemia
03/21/2024

Jordan Kadish

Jordan Kadish
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA...
03/21/2024
Oncology
News
Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Post-Transplantation
03/15/2024

Jordan Kadish

Jordan Kadish
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis...
03/15/2024
Oncology
News
FDA Grants Approval to Inotuzumab Ozogamicin for Pediatric Patients With R/R CD22-Positive B-Cell Precursor ALL
03/07/2024

Jordan Kadish

Jordan Kadish
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA...
03/07/2024
Oncology
News
Chemo-Free Induction/Consolidation With Dasatinib and Blinatumomab Shows Long-Term Responses for Adult Patients With Philadelphia-Positive ALL
02/21/2024
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free...
02/21/2024
Oncology
News
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin, and Blinatumomab Shows Safety, Efficacy Among Patients With Philadelphia Chromosome-Negative B-Cell ALL
02/13/2024
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD,...
02/13/2024
Oncology

Interactive Features

Quiz
Efficacy of Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Following ASCT
04/02/2024
04/02/2024
Oncology
Quiz
R/R Pre-B ALL Treatment With Mini-Hyper CVD Chemotherapy Plus Inotuzumab Ozogamicin With or Without Blinatumomab
08/01/2023
True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.
True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.
True or False: A treatment...
08/01/2023
Oncology
Quiz
Quiz: Use of Inotuzumab Ozogamicin Induction Therapy for De Novo Acute B-Lymphoblastic Leukemia
03/01/2023
True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.
True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.
True or False: 3 cycles of...
03/01/2023
Oncology
Quiz
Use of Blinatumomab During Consolidation for High-Risk Ph-Negative B-Cell Precursor ALL
03/01/2023
True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.
True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.
True or False: The use of...
03/01/2023
Oncology
Quiz
Quiz: ASCT From Matched Sibling Donors vs Matched Unrelated Donors in Adult High-Risk ALL
10/05/2022
True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.
True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.
True or False: Allogeneic...
10/05/2022
Oncology
Quiz
Quiz: Complete Remission Rate Among Patients With R/R B-Cell ALL With Anti-CD19 CAR T-Cell Therapy
08/23/2022
True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.
True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.
True or false: The complete...
08/23/2022
Oncology
Quiz
Quiz: Patients With ALL Are More Likely to Receive Salvage Chemotherapy After Treatment With Which Prior Therapy?
08/05/2022
True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...
True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...
True or False: Findings from the...
08/05/2022
Oncology
Phone
Quiz
Quiz: Is This CAR-T Therapy a Potential Treatment Option for R/R B-ALL?
03/07/2022
True or false: According to the phase 2 ZUMA-3 trial, brexucabtagene autoleucel may offer a treatment option for patients with R/R B-ALL.
True or false: According to the phase 2 ZUMA-3 trial, brexucabtagene autoleucel may offer a treatment option for patients with R/R B-ALL.
True or false: According to the...
03/07/2022
Oncology
Medical
Test Your Knowledge
Quiz: How Does Tisagenlecleucel Affect Activity in ALL?
03/07/2022
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel...
03/07/2022
Oncology
Quiz
Quiz: Which Disease Has a Historic Global Shortage of Drugs?
08/09/2021
Multiple Choice: In which disease is there a global shortage of critical drugs due to supply issues?
Multiple Choice: In which disease is there a global shortage of critical drugs due to supply issues?
Multiple Choice: In which...
08/09/2021
Oncology

Recent News

FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Blinatumomab Added to Consolidation Chemotherapy Improves Overall Survival Among Patients in MRD-Negative Remission From B-Cell Precursor ALL
08/14/2024
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study,...
08/14/2024
Oncology
News
FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL
06/21/2024
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to...
06/21/2024
Oncology
News
Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL
04/09/2024

Jordan Kadish

Jordan Kadish
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial,...
04/09/2024
Oncology
News
Allogeneic Stem Cell Transplantation in First Complete Remission for Patients With Philadelphia Chromosome-Positive ALL
04/01/2024

Jordan Kadish

Jordan Kadish
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia...
04/01/2024
Oncology
FDA Approval
FDA Approves Ponatinib With Chemotherapy for Patients With Newly-Diagnosed Ph-Positive Acute Lymphoblastic Leukemia
03/21/2024

Jordan Kadish

Jordan Kadish
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
On March 19, 2024, the US FDA...
03/21/2024
Oncology
News
Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Post-Transplantation
03/15/2024

Jordan Kadish

Jordan Kadish
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...
Imatinib prophylaxis...
03/15/2024
Oncology
News
FDA Grants Approval to Inotuzumab Ozogamicin for Pediatric Patients With R/R CD22-Positive B-Cell Precursor ALL
03/07/2024

Jordan Kadish

Jordan Kadish
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
On March 6, 2024, the FDA...
03/07/2024
Oncology
News
Chemo-Free Induction/Consolidation With Dasatinib and Blinatumomab Shows Long-Term Responses for Adult Patients With Philadelphia-Positive ALL
02/21/2024
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free induction/consolidation with dasatinib and blinatumomab prompted durable long-term responses among adult patients with Philadelphia-positive acute lymphoblastic leukemia, according to the final analysis of the D-ALBA trial.
Chemotherapy-free...
02/21/2024
Oncology
News
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin, and Blinatumomab Shows Safety, Efficacy Among Patients With Philadelphia Chromosome-Negative B-Cell ALL
02/13/2024
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD,...
02/13/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use